Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has received a consensus recommendation of “Moderate Buy” from the twenty-five brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and nineteen have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $304.26.

A number of brokerages have commented on ALNY. Morgan Stanley increased their price target on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. JPMorgan Chase & Co. increased their price target on shares of Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the company a “neutral” rating in a research report on Tuesday, March 11th. Canaccord Genuity Group raised their target price on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a “buy” rating in a report on Tuesday, February 18th. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. Finally, Scotiabank cut their target price on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating on the stock in a report on Friday, February 14th.

Alnylam Pharmaceuticals Stock Up 0.1 %

Shares of NASDAQ ALNY opened at $253.60 on Friday. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $304.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The firm’s 50 day simple moving average is $256.25 and its two-hundred day simple moving average is $259.51. The stock has a market capitalization of $32.83 billion, a P/E ratio of -116.87 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, analysts expect that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares of the company’s stock, valued at approximately $3,240,344.36. This trade represents a 10.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Yvonne Greenstreet sold 1,213 shares of the firm’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the transaction, the chief executive officer now directly owns 81,526 shares of the company’s stock, valued at $20,802,989.42. This represents a 1.47 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several large investors have recently modified their holdings of ALNY. Larson Financial Group LLC raised its position in shares of Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 73 shares during the last quarter. Park Square Financial Group LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $28,000. R Squared Ltd purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $33,000. OFI Invest Asset Management purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $35,000. Finally, Colonial Trust Co SC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $35,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.